nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—CREB1—telencephalic ventricle—malignant glioma	0.0337	0.143	CbGeAlD
Naloxone—OPRM1—telencephalic ventricle—malignant glioma	0.0182	0.0773	CbGeAlD
Naloxone—TLR4—cerebellum—malignant glioma	0.0102	0.0434	CbGeAlD
Naloxone—CREB1—embryo—malignant glioma	0.00996	0.0423	CbGeAlD
Naloxone—CREB1—brainstem—malignant glioma	0.00913	0.0388	CbGeAlD
Naloxone—CREB1—retina—malignant glioma	0.00881	0.0374	CbGeAlD
Naloxone—TLR4—brain—malignant glioma	0.00831	0.0353	CbGeAlD
Naloxone—CREB1—telencephalon—malignant glioma	0.0081	0.0344	CbGeAlD
Naloxone—ESR1—blood vessel—malignant glioma	0.00657	0.0279	CbGeAlD
Naloxone—OPRD1—telencephalon—malignant glioma	0.0064	0.0272	CbGeAlD
Naloxone—CREB1—medulla oblongata—malignant glioma	0.00637	0.0271	CbGeAlD
Naloxone—Grand mal convulsion—Carmustine—malignant glioma	0.00601	0.0917	CcSEcCtD
Naloxone—CREB1—midbrain—malignant glioma	0.00582	0.0247	CbGeAlD
Naloxone—CREB1—spinal cord—malignant glioma	0.00568	0.0241	CbGeAlD
Naloxone—OPRM1—brainstem—malignant glioma	0.00492	0.0209	CbGeAlD
Naloxone—CREB1—central nervous system—malignant glioma	0.0046	0.0196	CbGeAlD
Naloxone—CREB1—cerebellum—malignant glioma	0.0045	0.0191	CbGeAlD
Naloxone—Encephalopathy—Carmustine—malignant glioma	0.00446	0.068	CcSEcCtD
Naloxone—OPRM1—telencephalon—malignant glioma	0.00437	0.0186	CbGeAlD
Naloxone—ESR1—embryo—malignant glioma	0.00392	0.0167	CbGeAlD
Naloxone—SLCO1A2—telencephalon—malignant glioma	0.00376	0.016	CbGeAlD
Naloxone—CREB1—brain—malignant glioma	0.00366	0.0155	CbGeAlD
Naloxone—OPRD1—central nervous system—malignant glioma	0.00364	0.0155	CbGeAlD
Naloxone—ESR1—brainstem—malignant glioma	0.00359	0.0153	CbGeAlD
Naloxone—Buprenorphine—CYP2C18—malignant glioma	0.00352	0.675	CrCbGaD
Naloxone—OPRK1—central nervous system—malignant glioma	0.00349	0.0148	CbGeAlD
Naloxone—OPRK1—cerebellum—malignant glioma	0.00341	0.0145	CbGeAlD
Naloxone—ESR1—telencephalon—malignant glioma	0.00319	0.0136	CbGeAlD
Naloxone—OPRM1—midbrain—malignant glioma	0.00314	0.0133	CbGeAlD
Naloxone—OPRM1—spinal cord—malignant glioma	0.00306	0.013	CbGeAlD
Naloxone—SLCO1A2—medulla oblongata—malignant glioma	0.00295	0.0126	CbGeAlD
Naloxone—OPRD1—brain—malignant glioma	0.00289	0.0123	CbGeAlD
Naloxone—Injection site reaction—Carmustine—malignant glioma	0.00285	0.0434	CcSEcCtD
Naloxone—OPRK1—brain—malignant glioma	0.00277	0.0118	CbGeAlD
Naloxone—SLCO1A2—midbrain—malignant glioma	0.0027	0.0115	CbGeAlD
Naloxone—SLCO1A2—spinal cord—malignant glioma	0.00263	0.0112	CbGeAlD
Naloxone—Coma—Carmustine—malignant glioma	0.00262	0.0399	CcSEcCtD
Naloxone—ABCB1—blood vessel—malignant glioma	0.0026	0.011	CbGeAlD
Naloxone—OPRM1—central nervous system—malignant glioma	0.00248	0.0105	CbGeAlD
Naloxone—Hot flush—Temozolomide—malignant glioma	0.00215	0.0328	CcSEcCtD
Naloxone—SLCO1A2—central nervous system—malignant glioma	0.00214	0.00908	CbGeAlD
Naloxone—Menopausal symptoms—Temozolomide—malignant glioma	0.00213	0.0325	CcSEcCtD
Naloxone—SLCO1A2—cerebellum—malignant glioma	0.00209	0.00888	CbGeAlD
Naloxone—OPRM1—brain—malignant glioma	0.00197	0.00838	CbGeAlD
Naloxone—ESR1—central nervous system—malignant glioma	0.00181	0.0077	CbGeAlD
Naloxone—ESR1—cerebellum—malignant glioma	0.00177	0.00753	CbGeAlD
Naloxone—SLCO1A2—brain—malignant glioma	0.0017	0.00721	CbGeAlD
Naloxone—Hydromorphone—PTGS1—malignant glioma	0.00169	0.325	CrCbGaD
Naloxone—ALB—brain—malignant glioma	0.00169	0.00717	CbGeAlD
Naloxone—Depression—Carmustine—malignant glioma	0.0016	0.0244	CcSEcCtD
Naloxone—ABCB1—embryo—malignant glioma	0.00155	0.00658	CbGeAlD
Naloxone—Depression—Temozolomide—malignant glioma	0.00154	0.0235	CcSEcCtD
Naloxone—ESR1—brain—malignant glioma	0.00144	0.00612	CbGeAlD
Naloxone—Hallucination—Carmustine—malignant glioma	0.00143	0.0218	CcSEcCtD
Naloxone—Hallucination—Temozolomide—malignant glioma	0.00138	0.0211	CcSEcCtD
Naloxone—ABCB1—retina—malignant glioma	0.00137	0.00582	CbGeAlD
Naloxone—Flushing—Carmustine—malignant glioma	0.00133	0.0204	CcSEcCtD
Naloxone—Flushing—Temozolomide—malignant glioma	0.00129	0.0197	CcSEcCtD
Naloxone—Cardiac disorder—Temozolomide—malignant glioma	0.00129	0.0197	CcSEcCtD
Naloxone—Angiopathy—Temozolomide—malignant glioma	0.00126	0.0192	CcSEcCtD
Naloxone—ABCB1—telencephalon—malignant glioma	0.00126	0.00535	CbGeAlD
Naloxone—Mental disorder—Carmustine—malignant glioma	0.00126	0.0192	CcSEcCtD
Naloxone—Mediastinal disorder—Temozolomide—malignant glioma	0.00125	0.0191	CcSEcCtD
Naloxone—Chills—Temozolomide—malignant glioma	0.00125	0.019	CcSEcCtD
Naloxone—Mental disorder—Temozolomide—malignant glioma	0.00122	0.0186	CcSEcCtD
Naloxone—CYP2C8—brain—malignant glioma	0.00119	0.00504	CbGeAlD
Naloxone—Tremor—Carmustine—malignant glioma	0.00117	0.0179	CcSEcCtD
Naloxone—Agitation—Carmustine—malignant glioma	0.00115	0.0175	CcSEcCtD
Naloxone—Tremor—Temozolomide—malignant glioma	0.00113	0.0173	CcSEcCtD
Naloxone—Agitation—Temozolomide—malignant glioma	0.00111	0.017	CcSEcCtD
Naloxone—Convulsion—Carmustine—malignant glioma	0.00108	0.0165	CcSEcCtD
Naloxone—Hypertension—Carmustine—malignant glioma	0.00108	0.0165	CcSEcCtD
Naloxone—Convulsion—Temozolomide—malignant glioma	0.00105	0.016	CcSEcCtD
Naloxone—Hypertension—Temozolomide—malignant glioma	0.00104	0.0159	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00102	0.0156	CcSEcCtD
Naloxone—CYP3A4—central nervous system—malignant glioma	0.00101	0.0043	CbGeAlD
Naloxone—Tachycardia—Carmustine—malignant glioma	0.000997	0.0152	CcSEcCtD
Naloxone—ABCB1—medulla oblongata—malignant glioma	0.00099	0.00421	CbGeAlD
Naloxone—Nervous system disorder—Temozolomide—malignant glioma	0.000968	0.0148	CcSEcCtD
Naloxone—Skin disorder—Temozolomide—malignant glioma	0.000959	0.0146	CcSEcCtD
Naloxone—Hyperhidrosis—Temozolomide—malignant glioma	0.000954	0.0146	CcSEcCtD
Naloxone—Paraesthesia—Carmustine—malignant glioma	0.000917	0.014	CcSEcCtD
Naloxone—Dyspnoea—Carmustine—malignant glioma	0.000911	0.0139	CcSEcCtD
Naloxone—ABCB1—midbrain—malignant glioma	0.000905	0.00384	CbGeAlD
Naloxone—Paraesthesia—Temozolomide—malignant glioma	0.000886	0.0135	CcSEcCtD
Naloxone—ABCB1—spinal cord—malignant glioma	0.000883	0.00375	CbGeAlD
Naloxone—Gastrointestinal disorder—Carmustine—malignant glioma	0.000882	0.0135	CcSEcCtD
Naloxone—Dyspnoea—Temozolomide—malignant glioma	0.00088	0.0134	CcSEcCtD
Naloxone—Pain—Carmustine—malignant glioma	0.000873	0.0133	CcSEcCtD
Naloxone—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000852	0.013	CcSEcCtD
Naloxone—Pain—Temozolomide—malignant glioma	0.000844	0.0129	CcSEcCtD
Naloxone—Abdominal pain—Carmustine—malignant glioma	0.000807	0.0123	CcSEcCtD
Naloxone—Body temperature increased—Carmustine—malignant glioma	0.000807	0.0123	CcSEcCtD
Naloxone—Body temperature increased—Temozolomide—malignant glioma	0.00078	0.0119	CcSEcCtD
Naloxone—Abdominal pain—Temozolomide—malignant glioma	0.00078	0.0119	CcSEcCtD
Naloxone—Asthenia—Carmustine—malignant glioma	0.000733	0.0112	CcSEcCtD
Naloxone—ABCB1—central nervous system—malignant glioma	0.000716	0.00304	CbGeAlD
Naloxone—Asthenia—Temozolomide—malignant glioma	0.000708	0.0108	CcSEcCtD
Naloxone—ABCB1—cerebellum—malignant glioma	0.0007	0.00297	CbGeAlD
Naloxone—Diarrhoea—Carmustine—malignant glioma	0.000699	0.0107	CcSEcCtD
Naloxone—Diarrhoea—Temozolomide—malignant glioma	0.000675	0.0103	CcSEcCtD
Naloxone—Vomiting—Carmustine—malignant glioma	0.000649	0.00991	CcSEcCtD
Naloxone—Vomiting—Temozolomide—malignant glioma	0.000628	0.00958	CcSEcCtD
Naloxone—Nausea—Carmustine—malignant glioma	0.000607	0.00926	CcSEcCtD
Naloxone—Nausea—Temozolomide—malignant glioma	0.000586	0.00895	CcSEcCtD
Naloxone—ABCB1—brain—malignant glioma	0.000568	0.00242	CbGeAlD
Naloxone—OPRD1—GPCR downstream signaling—PIK3CA—malignant glioma	3.24e-05	4.67e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—SLC5A5—malignant glioma	3.23e-05	4.65e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGF—malignant glioma	3.22e-05	4.65e-05	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—AKT1—malignant glioma	3.22e-05	4.65e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—KRAS—malignant glioma	3.21e-05	4.63e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—SLC5A5—malignant glioma	3.21e-05	4.63e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTPN11—malignant glioma	3.2e-05	4.62e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—KRAS—malignant glioma	3.2e-05	4.61e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PDGFB—malignant glioma	3.19e-05	4.6e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FGFR1—malignant glioma	3.18e-05	4.58e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CD—malignant glioma	3.18e-05	4.58e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	3.17e-05	4.57e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—STAT3—malignant glioma	3.16e-05	4.55e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PDGFRA—malignant glioma	3.15e-05	4.54e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—FGF2—malignant glioma	3.14e-05	4.53e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—FGF2—malignant glioma	3.13e-05	4.51e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HIF1A—malignant glioma	3.13e-05	4.51e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—EGFR—malignant glioma	3.11e-05	4.48e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—BRAF—malignant glioma	3.07e-05	4.42e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS1—malignant glioma	3.06e-05	4.42e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL2—malignant glioma	3.06e-05	4.42e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SPP1—malignant glioma	3.06e-05	4.41e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—IDH2—malignant glioma	3.06e-05	4.4e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	3.05e-05	4.4e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	3.04e-05	4.38e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	3.03e-05	4.36e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CAV1—malignant glioma	3.03e-05	4.36e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	3.01e-05	4.34e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KDR—malignant glioma	2.99e-05	4.31e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AKT2—malignant glioma	2.98e-05	4.3e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—malignant glioma	2.97e-05	4.28e-05	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—RAF1—malignant glioma	2.96e-05	4.26e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—PIK3CA—malignant glioma	2.95e-05	4.25e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—PIK3CA—malignant glioma	2.94e-05	4.24e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MDM2—malignant glioma	2.94e-05	4.24e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—KRAS—malignant glioma	2.93e-05	4.23e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MYC—malignant glioma	2.93e-05	4.23e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MDM2—malignant glioma	2.93e-05	4.22e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RAF1—malignant glioma	2.93e-05	4.22e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RAF1—malignant glioma	2.92e-05	4.21e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TERT—malignant glioma	2.9e-05	4.18e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ERBB2—malignant glioma	2.9e-05	4.18e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ERBB2—malignant glioma	2.89e-05	4.16e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FN1—malignant glioma	2.88e-05	4.15e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—F2—malignant glioma	2.88e-05	4.15e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2B6—malignant glioma	2.87e-05	4.14e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—malignant glioma	2.87e-05	4.13e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CD—malignant glioma	2.87e-05	4.13e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CB—malignant glioma	2.86e-05	4.12e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CB—malignant glioma	2.85e-05	4.11e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—BCHE—malignant glioma	2.85e-05	4.11e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—BAD—malignant glioma	2.85e-05	4.1e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—PIK3CA—malignant glioma	2.84e-05	4.09e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PDGFB—malignant glioma	2.83e-05	4.08e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOTCH1—malignant glioma	2.82e-05	4.06e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FGFR1—malignant glioma	2.82e-05	4.06e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SLC5A5—malignant glioma	2.81e-05	4.06e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—KRAS—malignant glioma	2.81e-05	4.05e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HIF1A—malignant glioma	2.77e-05	4e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CB—malignant glioma	2.77e-05	3.99e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CD80—malignant glioma	2.76e-05	3.98e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APC—malignant glioma	2.76e-05	3.97e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CG—malignant glioma	2.76e-05	3.97e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL8—malignant glioma	2.75e-05	3.96e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—FGF2—malignant glioma	2.75e-05	3.96e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—malignant glioma	2.74e-05	3.95e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL8—malignant glioma	2.74e-05	3.95e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGF—malignant glioma	2.73e-05	3.93e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—KRAS—malignant glioma	2.71e-05	3.9e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTPN11—malignant glioma	2.71e-05	3.9e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—PIK3CA—malignant glioma	2.7e-05	3.89e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CAV1—malignant glioma	2.68e-05	3.87e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KDR—malignant glioma	2.65e-05	3.82e-05	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AKT1—malignant glioma	2.65e-05	3.81e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	2.64e-05	3.8e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CASP3—malignant glioma	2.63e-05	3.79e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—IDH1—malignant glioma	2.63e-05	3.79e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2—malignant glioma	2.63e-05	3.78e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	2.62e-05	3.78e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CASP3—malignant glioma	2.62e-05	3.78e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2—malignant glioma	2.62e-05	3.77e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—malignant glioma	2.6e-05	3.75e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTP1—malignant glioma	2.6e-05	3.75e-05	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	2.59e-05	3.74e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—BRAF—malignant glioma	2.59e-05	3.73e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTP1—malignant glioma	2.59e-05	3.73e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PIK3CA—malignant glioma	2.58e-05	3.72e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MDM2—malignant glioma	2.57e-05	3.7e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RAF1—malignant glioma	2.56e-05	3.69e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—F2—malignant glioma	2.55e-05	3.68e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FN1—malignant glioma	2.55e-05	3.68e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SPHK1—malignant glioma	2.54e-05	3.66e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB2—malignant glioma	2.53e-05	3.65e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CAT—malignant glioma	2.53e-05	3.65e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—BAD—malignant glioma	2.52e-05	3.64e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AKT2—malignant glioma	2.52e-05	3.64e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CAT—malignant glioma	2.52e-05	3.63e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—malignant glioma	2.51e-05	3.62e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOTCH1—malignant glioma	2.5e-05	3.6e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CB—malignant glioma	2.5e-05	3.6e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2C18—malignant glioma	2.49e-05	3.59e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PIK3CA—malignant glioma	2.49e-05	3.59e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP9—malignant glioma	2.49e-05	3.58e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—malignant glioma	2.48e-05	3.57e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTEN—malignant glioma	2.47e-05	3.56e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTEN—malignant glioma	2.46e-05	3.55e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CD80—malignant glioma	2.45e-05	3.53e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APC—malignant glioma	2.44e-05	3.52e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CG—malignant glioma	2.44e-05	3.52e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CD—malignant glioma	2.42e-05	3.49e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGF—malignant glioma	2.42e-05	3.48e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AKT1—malignant glioma	2.41e-05	3.47e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AKT1—malignant glioma	2.4e-05	3.46e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL8—malignant glioma	2.4e-05	3.46e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTPN11—malignant glioma	2.4e-05	3.46e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—PIK3CA—malignant glioma	2.4e-05	3.46e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTEN—malignant glioma	2.39e-05	3.45e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NCOR1—malignant glioma	2.39e-05	3.45e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—NCOR1—malignant glioma	2.38e-05	3.43e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—malignant glioma	2.37e-05	3.42e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FGF2—malignant glioma	2.32e-05	3.34e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AKT1—malignant glioma	2.32e-05	3.34e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CASP3—malignant glioma	2.3e-05	3.31e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—BRAF—malignant glioma	2.3e-05	3.31e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—malignant glioma	2.3e-05	3.31e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—malignant glioma	2.27e-05	3.27e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT2—malignant glioma	2.24e-05	3.22e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—malignant glioma	2.23e-05	3.22e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—malignant glioma	2.22e-05	3.21e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—malignant glioma	2.21e-05	3.19e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—STAT3—malignant glioma	2.21e-05	3.18e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CAT—malignant glioma	2.21e-05	3.18e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—STAT3—malignant glioma	2.2e-05	3.17e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—AKT1—malignant glioma	2.2e-05	3.17e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PIK3CA—malignant glioma	2.18e-05	3.14e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—malignant glioma	2.17e-05	3.13e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MDM2—malignant glioma	2.17e-05	3.13e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RAF1—malignant glioma	2.16e-05	3.12e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTEN—malignant glioma	2.16e-05	3.11e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CD—malignant glioma	2.15e-05	3.1e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB2—malignant glioma	2.14e-05	3.08e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CB—malignant glioma	2.11e-05	3.04e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AKT1—malignant glioma	2.11e-05	3.04e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NCOR1—malignant glioma	2.08e-05	3e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MYC—malignant glioma	2.07e-05	2.98e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FGF2—malignant glioma	2.06e-05	2.97e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MYC—malignant glioma	2.05e-05	2.96e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MYC—malignant glioma	2.05e-05	2.95e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PIK3CA—malignant glioma	2.03e-05	2.93e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—AKT1—malignant glioma	2.03e-05	2.93e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—malignant glioma	2.03e-05	2.93e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTT1—malignant glioma	2.01e-05	2.9e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—malignant glioma	2.01e-05	2.89e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—malignant glioma	2e-05	2.89e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—malignant glioma	1.97e-05	2.84e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AKT1—malignant glioma	1.96e-05	2.83e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—malignant glioma	1.95e-05	2.81e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CAV1—malignant glioma	1.95e-05	2.81e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CASP3—malignant glioma	1.94e-05	2.8e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—malignant glioma	1.94e-05	2.8e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CAV1—malignant glioma	1.94e-05	2.79e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—STAT3—malignant glioma	1.93e-05	2.78e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MDM2—malignant glioma	1.93e-05	2.77e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RAF1—malignant glioma	1.92e-05	2.76e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB2—malignant glioma	1.9e-05	2.74e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—malignant glioma	1.9e-05	2.73e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—malignant glioma	1.89e-05	2.73e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS1—malignant glioma	1.89e-05	2.72e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CB—malignant glioma	1.87e-05	2.7e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.86e-05	2.68e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.85e-05	2.67e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—malignant glioma	1.84e-05	2.65e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTEN—malignant glioma	1.83e-05	2.63e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—malignant glioma	1.8e-05	2.59e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MYC—malignant glioma	1.79e-05	2.59e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AKT1—malignant glioma	1.78e-05	2.57e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CG—malignant glioma	1.78e-05	2.56e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CG—malignant glioma	1.77e-05	2.54e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—malignant glioma	1.76e-05	2.53e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—BCHE—malignant glioma	1.76e-05	2.53e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CA—malignant glioma	1.74e-05	2.51e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CA—malignant glioma	1.74e-05	2.5e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC5A5—malignant glioma	1.73e-05	2.5e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CASP3—malignant glioma	1.72e-05	2.48e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—malignant glioma	1.72e-05	2.48e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARG—malignant glioma	1.71e-05	2.47e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARG—malignant glioma	1.7e-05	2.46e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CAV1—malignant glioma	1.7e-05	2.45e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CA—malignant glioma	1.69e-05	2.43e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—malignant glioma	1.69e-05	2.43e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—malignant glioma	1.68e-05	2.42e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—AKT1—malignant glioma	1.66e-05	2.39e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—malignant glioma	1.66e-05	2.39e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—malignant glioma	1.65e-05	2.38e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STAT3—malignant glioma	1.63e-05	2.35e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—malignant glioma	1.63e-05	2.35e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTEN—malignant glioma	1.62e-05	2.33e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CD—malignant glioma	1.56e-05	2.25e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CD—malignant glioma	1.55e-05	2.24e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CG—malignant glioma	1.55e-05	2.23e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CA—malignant glioma	1.52e-05	2.2e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MYC—malignant glioma	1.52e-05	2.19e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARG—malignant glioma	1.49e-05	2.15e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—malignant glioma	1.48e-05	2.14e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—malignant glioma	1.47e-05	2.12e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—malignant glioma	1.46e-05	2.11e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STAT3—malignant glioma	1.45e-05	2.09e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—AKT1—malignant glioma	1.43e-05	2.07e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AKT1—malignant glioma	1.42e-05	2.05e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AKT1—malignant glioma	1.42e-05	2.05e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—malignant glioma	1.4e-05	2.02e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—malignant glioma	1.4e-05	2.01e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AKT1—malignant glioma	1.38e-05	1.99e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CB—malignant glioma	1.36e-05	1.96e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CD—malignant glioma	1.36e-05	1.96e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CAT—malignant glioma	1.36e-05	1.96e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CB—malignant glioma	1.35e-05	1.95e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—malignant glioma	1.35e-05	1.94e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MYC—malignant glioma	1.35e-05	1.94e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—malignant glioma	1.34e-05	1.93e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—malignant glioma	1.32e-05	1.9e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CA—malignant glioma	1.29e-05	1.86e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NCOR1—malignant glioma	1.28e-05	1.85e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—malignant glioma	1.25e-05	1.8e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AKT1—malignant glioma	1.24e-05	1.79e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—malignant glioma	1.24e-05	1.79e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CB—malignant glioma	1.19e-05	1.71e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTEN—malignant glioma	1.18e-05	1.69e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—malignant glioma	1.17e-05	1.69e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTEN—malignant glioma	1.17e-05	1.68e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CA—malignant glioma	1.14e-05	1.65e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—malignant glioma	1.1e-05	1.59e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AKT1—malignant glioma	1.05e-05	1.52e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CAV1—malignant glioma	1.05e-05	1.51e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTEN—malignant glioma	1.02e-05	1.48e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CG—malignant glioma	9.53e-06	1.37e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT1—malignant glioma	9.33e-06	1.34e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARG—malignant glioma	9.2e-06	1.33e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CD—malignant glioma	8.38e-06	1.21e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CA—malignant glioma	8.29e-06	1.2e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CA—malignant glioma	8.25e-06	1.19e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CB—malignant glioma	7.3e-06	1.05e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—malignant glioma	7.24e-06	1.04e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CA—malignant glioma	7.23e-06	1.04e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AKT1—malignant glioma	6.77e-06	9.76e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—AKT1—malignant glioma	6.74e-06	9.71e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTEN—malignant glioma	6.31e-06	9.09e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AKT1—malignant glioma	5.9e-06	8.51e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CA—malignant glioma	4.45e-06	6.41e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKT1—malignant glioma	3.64e-06	5.24e-06	CbGpPWpGaD
